Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients

Recruiting

Phase 2

EI-001Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients

Sponsor:

Elixiron Immunotherapeutics (Hong Kong) Ltd.

Code:

NCT07223229

Conditions

Non-segmental Vitiligo

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

EI-001

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-10. This information was provided to ClinicalTrials.gov by Elixiron Immunotherapeutics (Hong Kong) Ltd. on 2026-06-05.